Efficacy And Safety Of IFN A-2b In Antiviral Therapy For Patients With Post-hepatitis B Compensated Cirrhosis

Objective:To analyze the efficacy and safety of IFN a-2b in antiviral therapy for patients with post-hepatitis B compensated cirrhosis,and to provide reference for the clinical treatment of compensated cirrhosis.Methods:A total of 75 patients with post-hepatitis B compensated cirrhosis in our hospital were collected from 2012 to 2015.According to different treatment methods,they were divided into interferon group and nucleoside drug group,interferon group 23 cases,nucleoside drug group 52 cases.The general data of the two groups were not significantly different,and decompensated cirrhosis,liver failure,cardiovascular complications and kidney damage were excluded.In the treatment method,two groups of patients all need to use conventional drug treatment.The interferon antiviral group using interferon antiviral treatment,in the treatment method,the use of A2B interferon,each 6MU subcutaneous injection,once a day,treatment for four weeks.Four weeks later,A2B interferon was injected subcutaneously 30MU per week for a total of 52 weeks.The nucleoside group was treated with nucleotide drugs.In this study,5 cases were treated with A Duff Vee,12 cases were treated with lamivudine,and 35 cases were treated with entecavir.After 4 weeks,12 weeks,24 weeks and 52 weeks,the treatment effect and adverse reactions and complications during treatment were collected and analyzed.Result:1.The liver function indexes of the two groups were significantly different from those before treatment(P<0.01).At the 4th week of treatment,the liver function indexes of patients in interferon antiviral group were significantly different from those in nucleoside group(P<0.01).Among them,AST,ALT indicators of patients in the interferon antiviral group appeared short-term fluctuations,while ALB,GLB and CHE indicators were better than the nucleoside drug group patients.At the 12th and 24th week of treatment,there was no significant difference in liver function between the two groups(P>0.05).At week 52,the rate of ALT negative in patients of interferon antiviral group(82.61%)was significantly higher than that in patients of nucleoside group(57.69%)(P<0.05).2.After treatment,the HBVDNA negative rate in interferon antiviral group was lower than that in nucleoside group at each time point,the difference was statistically significant(P<0.05).There was no significant difference in the rate of HBsAg clearance between the two groups at each time point(P>0.05).The HBeAg negative rate in the interferon antiviral group was not significantly different from that in the nucleoside drug group in the early observation period(P>0.05).However,the HBeAg negative rate in the interferon group was higher than that in the nucleoside group patients,the difference was statistically significant(P<0.05).3.Adverse reactions occurred in both groups,but not serious.There was no significant difference in the incidence of adverse reactions between the two groups at each time point(P>0.05).Conclusion:1.Interferon treatment of patients with decompensated hepatitis B can be effective and effective clinical curative effect,compared with the nucleotide treatment,the AST,ALT indicators,only in the early treatment of relatively short-term fluctuations,and have more advantages in the ALB,GLB and CHE indicators to improve.And late treatment,access to higher rates of abnormal ALT and HBeAg negative conversion rate.2.The use of interferon in treatment of decompensated liver cirrhosis patients with high safety,only in the first 4 weeks of treatment with fever,blood cells decreased,but these complications are relatively minor,does not cause a greater impact on the efficacy and safety of treatment.3.In order to ensure the safety of treatment,it is necessary to pay attention to the reaction at the time of diagnosis and treatment.Once serious adverse reactions occur,the drug should be stopped immediately and symptomatic treatment should be taken.